Perspectives of D1 dopamine antagonists using in treatment of nervous and psychic disorders with (+)-SCH-23390 as an example
Author(s) -
Anna Alexandrovna Bukinich
Publication year - 2014
Publication title -
reviews on clinical pharmacology and drug therapy
Language(s) - English
Resource type - Journals
eISSN - 2542-1875
pISSN - 1683-4100
DOI - 10.17816/rcf12254-58
Subject(s) - sch 23390 , dopamine , agonist , neuroscience , dopamine receptor , chemistry , medicine , receptor , endocrinology , pharmacology , biology
The effect of dopamine (DA), its agonists and antagonists on the amplitude of GABA-activated currents of isolated multipolar spinal cord neurons (both motoneurons and interneurons) of larva of the lamprey Lampetra planeri by means of patch-clamp method in the whole cell configuration was studied. (+)-SCH-23390, a D1-DA receptors antagonist was shown to block dopamine effects on GABA-activated currents by 63.0 ± 4.7 % and by 77.1 ± 2.0 %. Effects of (-)quinpirol, a D2-DA receptors agonist, on GABA-activated currents were blocked by means of (+)-SCH-23390 by 78.8 ± 0.4 % and by 85.0 ± 5.7 %. Because of chemoactivated currents are in full accordance with a gradual scale, the results on blocking D1-DA receptors by (+)-SCH-23390 are ideal ones and that is the possible basis to further clinical aprobation of (+)-SCH-23390 for treatment of epilepsy, neurotic reactions and depression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom